Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts.

J Immunol

Department of Biochemistry and Molecular Biology, Immunology Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

Published: September 2002

The B cell Ag receptor (BCR) and CD20, a putative calcium channel, inducibly associate with cholesterol-dependent membrane microdomains known as lipid rafts. A functional association between the BCR and CD20 is suggested by the effects of CD20-specific mAbs, which can modulate cell cycle transitions elicited by BCR signaling. Using immunofluorescence microscopy we show here that the BCR and CD20 colocalize after receptor ligation and then rapidly dissociate at the cell surface before endocytosis of the BCR. After separation, surface BCR and CD20 were detected in distinct lipid rafts isolated as low density, detergent-resistant membrane fragments. Pretreatment with methyl-beta-cyclodextrin, which we have previously shown to enhance receptor-mediated calcium mobilization, did not prevent colocalization of the BCR and CD20, but slowed their dissociation. The data demonstrate rapid dynamics of the BCR in relation to CD20 at the cell surface. Activation-dependent dissociation of the BCR from CD20 occurs before receptor endocytosis and appears to require in part the integrity of lipid rafts.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.169.6.2886DOI Listing

Publication Analysis

Top Keywords

bcr cd20
24
lipid rafts
16
bcr
9
cell receptor
8
cd20
8
activation-dependent dissociation
8
distinct lipid
8
cell surface
8
colocalization cell
4
receptor
4

Similar Publications

Background: Immunotherapy has demonstrated limited activity in prostate cancer to date. This likely reflects an immune suppressive tumor microenvironment (TME), with previous studies suggesting low PD-L1 expression and a sparse immune cell infiltrate. We aimed to further characterise the immune TME in primary prostate cancer and correlate immune subset densities with clinical outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • * Out of 75 patients with successful BCR expression, a significant majority had mutated immunoglobulin heavy chains (IgVH), and a subgroup of 12 patients showed a highly dominant BCR clone associated with worse clinical outcomes.
  • * The results indicated that high clonal dominance correlates with reduced BCR diversity and increased expression of specific genes, leading to poorer progression-free survival (PFS) and overall survival (OS) rates, corroborated by an independent patient cohort analysis.
View Article and Find Full Text PDF

Rationale: Patients with relapsed and refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with the T315I mutation are at higher risk of relapse and have shorter overall survival.

Patient Concerns: A 31-year-old man presented to the hematology department with intermittent fever and pancytopenia. He was diagnosed with Ph+ acute lymphoblastic leukemia and experienced 2 relapses during treatment.

View Article and Find Full Text PDF

In this editorial, we discussed the apparent discrepancy between the findings described by Colapietro , in their case report and data found in the literature. Colapietro reported a case of hepatitis B virus (HBV)-related hepatic decompensation in a patient with chronic myeloid leukemia and a previously resolved HBV infection who was receiving Bruton's tyrosine kinase (BTK) inhibitor therapy. First of all, we recapitulated the main aspects of the immune system involved in the response to HBV infection in order to underline the role of the innate and adaptive response, focusing our attention on the protective role of anti-HBs.

View Article and Find Full Text PDF

Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.

Hematol Oncol

July 2024

Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic.

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. They target BTK, a key effector in the B-cell receptor (BCR) signaling pathway, crucial for B-cell survival and proliferation. The first-in-class irreversible BTK inhibitor, ibrutinib, was approved for various B-cell malignancies but has limitations due to off-target effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!